Searle Celebrex
Executive Summary
FDA's Oncologic Drugs Advisory Committee will review celecoxib for the regression and prevention of adenomatous polyps which may lead to the development of colorectal cancer in patients with familial adenomatous polyposis. The meeting will be held Dec. 14 at the Holiday Inn in Bethesda, Md. beginning at 8:30 a.m